CytomX TherapeuticsCTMX
CTMX
About: CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Employees: 121
0
Funds holding %
of 7,345 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
3.17% less ownership
Funds ownership: 59.69% [Q4 2024] → 56.52% (-3.17%) [Q1 2025]
6% less funds holding
Funds holding: 70 [Q4 2024] → 66 (-4) [Q1 2025]
23% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 26
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
40% less capital invested
Capital invested by funds: $48.1M [Q4 2024] → $28.8M (-$19.3M) [Q1 2025]
70% less call options, than puts
Call options by funds: $9K | Put options by funds: $30K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
184%
upside
Avg. target
$5.67
222%
upside
High target
$7
298%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Oppenheimer Matthew Biegler | 298%upside $7 | Outperform Initiated | 31 Jul 2025 |
HC Wainwright & Co. Mitchell Kapoor | 184%upside $5 | Buy Reiterated | 20 May 2025 |
Piper Sandler Joseph Catanzaro | 184%upside $5 | Overweight Maintained | 15 May 2025 |
Financial journalist opinion
Based on 7 articles about CTMX published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study
- The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company's goal of providing a Phase 1 data update in Q1 2026 - - The CTMX-2051-101 study remains active and patients continue to be dosed with CX-2051 across all expansion doses - SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today provided an update on the CX-2051 Phase 1 study to address certain recent social media posts.
Neutral
Seeking Alpha
5 days ago
CytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call Transcript
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Christopher W. Ogden - SVP & Chief Financial Officer Sean A.
Positive
Seeking Alpha
5 days ago
CytomX Therapeutics: Updated Outlook For Late 2025
I remain bullish on CytomX Therapeutics due to promising pipeline developments in masked antibody-based immunotherapies for cancer. CX-2051 shows strong disease control in refractory colorectal cancer, with manageable side effects, supporting continued clinical progress. Initiation of CX-801 phase 1 trial in metastatic melanoma, combined with pembrolizumab, marks a key milestone for the pipeline.
Neutral
The Motley Fool
6 days ago
CytomX (CTMX) Q2 Revenue Drops 26%
CytomX (CTMX) Q2 Revenue Drops 26%
Neutral
Zacks Investment Research
6 days ago
CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2
CytomX Therapeutics (CTMX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.08 per share a year ago.
Neutral
GlobeNewsWire
1 week ago
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) -
Neutral
GlobeNewsWire
2 weeks ago
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025
SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report second quarter financial results on Thursday, August 7, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
Neutral
GlobeNewsWire
2 months ago
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 2:35 p.m. ET.
Neutral
GlobeNewsWire
2 months ago
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma
SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the first patient has been dosed with CX-801 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in the ongoing Phase 1 dose escalation study (NCT06462794) evaluating safety and initial clinical activity in patients with metastatic melanoma.
Positive
Seeking Alpha
3 months ago
CytomX Therapeutics: Doubling Overnight On Phase 1 Data
CytomX Therapeutics' CX-2501 shows promising phase 1 results in refractory colorectal cancer, with a 27.8% objective response rate and manageable toxicity. CTMX's financial position strengthened by a $100 million stock offering, extending cash runway through 2025. CX-904 development with Amgen discontinued, but collaboration continues on a preclinical T-cell engager project.
Charts implemented using Lightweight Charts™